Last reviewed · How we verify
Placebo to match Hydroxycarbamide
This is a placebo formulation designed to match the appearance and administration of hydroxycarbamide for use as a control in clinical trials.
This is a placebo formulation designed to match the appearance and administration of hydroxycarbamide for use as a control in clinical trials. Used for Control arm in Phase 3 clinical trials (indication depends on the active hydroxycarbamide trial).
At a glance
| Generic name | Placebo to match Hydroxycarbamide |
|---|---|
| Sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo-to-match products are inert formulations engineered to be indistinguishable from the active drug in terms of appearance, taste, smell, and administration route. In this case, it mimics hydroxycarbamide (hydroxyurea) to serve as a control arm in Phase 3 trials, allowing for blinded comparison of the active drug's efficacy and safety against an inert comparator.
Approved indications
- Control arm in Phase 3 clinical trials (indication depends on the active hydroxycarbamide trial)
Common side effects
Key clinical trials
- Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease (PHASE2)
- Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis (PHASE3)
- A Pilot Therapeutic Trial Using Hydroxyurea in Type I Spinal Muscular Atrophy Patients (PHASE1, PHASE2)
- A Pilot Therapeutic Trial Using Hydroxyurea in Type II and Type III Spinal Muscular Atrophy Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: